Moomoo AI 已提取核心信息
On February 20, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorders and rare diseases, announced its ongoing collaboration with Clearmind Medicine Inc., a biotech company developing psychedelic-derived therapeutics. Together, they are strengthening their international patent portfolio with the filing of three new patent applications under the Patent Cooperation Treaty. These applications focus on novel combinations of psychedelic compounds, including LSD, psilocybin, DMT, and SciSparc's proprietary ingredient CannAmide™. The patents, initially filed as provisional applications with the USPTO, aim to leverage the therapeutic advantages of these compounds. SciSparc's CEO, Oz Adler, expressed confidence in the value CannAmide™ adds to psychedelic therapeutics. The company is also advancing drug development programs for various conditions, including Tourette Syndrome, Alzheimer's disease, pain, ASD, and status epilepticus, and owns a subsidiary selling hemp seed oil-based products on Amazon.
On February 20, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorders and rare diseases, announced its ongoing collaboration with Clearmind Medicine Inc., a biotech company developing psychedelic-derived therapeutics. Together, they are strengthening their international patent portfolio with the filing of three new patent applications under the Patent Cooperation Treaty. These applications focus on novel combinations of psychedelic compounds, including LSD, psilocybin, DMT, and SciSparc's proprietary ingredient CannAmide™. The patents, initially filed as provisional applications with the USPTO, aim to leverage the therapeutic advantages of these compounds. SciSparc's CEO, Oz Adler, expressed confidence in the value CannAmide™ adds to psychedelic therapeutics. The company is also advancing drug development programs for various conditions, including Tourette Syndrome, Alzheimer's disease, pain, ASD, and status epilepticus, and owns a subsidiary selling hemp seed oil-based products on Amazon.
2024年2月20日，专门研究中枢神经系统疾病和罕见疾病的临床阶段制药公司ScisPARC Ltd. 宣布与开发迷幻药衍生疗法的生物技术公司Clearmind Medicine Inc. 持续合作。他们共同根据《专利合作条约》提交了三项新的专利申请，从而加强了其国际专利组合。这些应用侧重于迷幻化合物的新组合，包括迷幻药、迷幻药、DMT和ScisPARC的专有成分CannaMide™。这些专利最初是作为临时申请向美国专利商标局提交的，旨在利用这些化合物的治疗优势。ScisPARC的首席执行官奥兹·阿德勒表示对CannaMide™ 为迷幻疗法增加的价值充满信心。该公司还在推进针对各种疾病的药物开发计划，包括图雷特综合症、阿尔茨海默氏病、疼痛、自闭症障碍和癫痫持续状态，并拥有一家在亚马逊上销售大麻籽油类产品的子公司。
2024年2月20日，专门研究中枢神经系统疾病和罕见疾病的临床阶段制药公司ScisPARC Ltd. 宣布与开发迷幻药衍生疗法的生物技术公司Clearmind Medicine Inc. 持续合作。他们共同根据《专利合作条约》提交了三项新的专利申请，从而加强了其国际专利组合。这些应用侧重于迷幻化合物的新组合，包括迷幻药、迷幻药、DMT和ScisPARC的专有成分CannaMide™。这些专利最初是作为临时申请向美国专利商标局提交的，旨在利用这些化合物的治疗优势。ScisPARC的首席执行官奥兹·阿德勒表示对CannaMide™ 为迷幻疗法增加的价值充满信心。该公司还在推进针对各种疾病的药物开发计划，包括图雷特综合症、阿尔茨海默氏病、疼痛、自闭症障碍和癫痫持续状态，并拥有一家在亚马逊上销售大麻籽油类产品的子公司。
有用
没用